Site icon OncologyTube

Bijal Shah, MD, MS [slides]- CART Cell Therapy for Refractory ALL

Bijal Shah, MD, MS- Hematology/Oncology- Moffitt Cancer Center

Bijal Shah MD, MS, emphasizes the positive outcomes of CAR T cell therapy for patients with relapsed refractory conditions, particularly those who have experienced multiple relapses and high tumor burdens. They highlight the success achieved with CAR T therapy, especially after treatment with Blinatumomab (Blina) and Inotuzumab Ozogamicin (I know).

REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS
AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/
AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/
MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/
Register – AML-ALL US Focus Meeting 2023
aml-allus2023.md-education.com

Bijal Shah MD, MS, compares CAR T therapy as a single agent to other immunotherapy approaches and stresses that the combination of these therapies can be transformative, akin to a seat belt and airbag working together for safety. They discuss the data demonstrating improved survival rates with CAR T cells, particularly for patients who had previously failed Blina and I know treatment. They also address challenges related to intercurrent infections and eligibility for CAR T treatment, emphasizing the need for earlier integration of CAR T therapy in the treatment pathway.

Exit mobile version